Cargando…
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
The incidence of invasive fungal diseases (IFDs) with central nervous system (CNS) involvement is increasing due to the rising numbers of immunocompromised individuals, such as patients receiving chemotherapy, transplantation procedures, or immune-modulating therapies. CNS IFDs cause significant mor...
Autores principales: | Schwartz, Stefan, Cornely, Oliver A, Hamed, Kamal, Marty, Francisco M, Maertens, Johan, Rahav, Galia, Herbrecht, Raoul, Heinz, Werner J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261609/ https://www.ncbi.nlm.nih.gov/pubmed/31613363 http://dx.doi.org/10.1093/mmy/myz103 |
Ejemplares similares
-
824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
por: Marty, Francisco M., et al.
Publicado: (2014) -
Isavuconazole for invasive fungal infections
Publicado: (2020) -
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018) -
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017) -
Role of isavuconazole in the treatment of invasive fungal infections
por: Wilson, Dustin T, et al.
Publicado: (2016)